CNAT Quote Trading Chart Conatus Pharmaceuticals

$0.556 Last:

0.18% Change Percent:

$0.59 Open:

$0.556 Previous Close:

$0.594 High:

$0.5406 Low:

1,638,707 Volume:

05/26/2020 04:46:22 am Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2020-05-26	0.59	0.556	0.594	0.5406	1,638,707
2020-05-25	0.63	0.555	0.63	0.525	3,043,177
2020-05-22	0.63	0.555	0.63	0.525	3,017,428
2020-05-21	0.66	0.58	0.75	0.4523	10,648,208
2020-05-20	0.688	0.6636	0.69	0.63	3,277,867
2020-05-19	0.64	0.67	0.72	0.6011	3,968,666
2020-05-18	0.602	0.645	0.66	0.5679	4,252,630
2020-05-15	0.6	0.6001	0.62	0.56	2,947,982
2020-05-14	0.5	0.626	0.66	0.49	8,031,946
2020-05-13	0.49	0.484	0.535	0.4515	3,392,913
2020-05-12	0.44	0.48	0.49	0.4134	3,908,074
2020-05-11	0.4153	0.43	0.4596	0.401	3,042,797
2020-05-08	0.402	0.4	0.4179	0.3602	2,375,155
2020-05-07	0.449	0.4574	0.515	0.4012	4,777,235
2020-05-06	0.5207	0.4399	0.54	0.4	5,886,170
2020-05-05	0.353	0.4726	0.498	0.3382	6,674,344
2020-05-04	0.345	0.3453	0.349	0.3329	67,252
2020-05-01	0.3598	0.342	0.3598	0.34	237,609
2020-04-30	0.3465	0.3565	0.3589	0.3333	206,779
2020-04-29	0.35	0.3499	0.352	0.3402	230,651

Stock Information

Conatus Pharmaceuticals Company Name:

CNAT Stock Symbol:

NASDAQ Market:

Conatus Pharmaceuticals Website:

Get CNAT Alerts

News, Short Squeeze, Breakout and More Instantly...

CNAT - Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split

SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional investors with voting assessment an...
CNAT - Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair ...
CNAT - Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) app...